• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The Response of Hemostatic Marker Levels to Activated Factor VII in a Neonate following Cardiopulmonary Bypass.体外循环后新生儿止血标志物水平对活化凝血因子VII的反应
Case Rep Med. 2009;2009:420152. doi: 10.1155/2009/420152. Epub 2009 Aug 31.
2
Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.在临床体外循环期间，表面结合的肝素未能减少凝血酶的形成。
J Thorac Cardiovasc Surg. 1996 Jan;111(1):1-11; discussion 11-2. doi: 10.1016/s0022-5223(96)70395-1.
3
Cardiopulmonary bypass parameters and hemostatic response to cardiopulmonary bypass in infants versus children.婴儿与儿童的体外循环参数及体外循环的止血反应
J Cardiothorac Vasc Anesth. 2008 Feb;22(1):53-9. doi: 10.1053/j.jvca.2007.06.006. Epub 2007 Aug 22.
4
Augmentation of thrombin generation in neonates undergoing cardiopulmonary bypass.新生儿体外循环中凝血酶生成的增强。
Br J Anaesth. 2014 Feb;112(2):319-27. doi: 10.1093/bja/aet355. Epub 2013 Nov 4.
5
Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations.心脏手术期间新生儿的纤维蛋白溶解、抗凝血酶III和蛋白C
J Thorac Cardiovasc Surg. 1996 Sep;112(3):665-71. doi: 10.1016/S0022-5223(96)70050-8.
6
Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.使用含有孕二烯酮或左炔诺孕酮的低剂量复方口服避孕药两年后对止血的影响。
Clin Appl Thromb Hemost. 1999 Jan;5(1):60-70. doi: 10.1177/107602969900500112.
7
Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.口服避孕药引起的血液凝固和纤维蛋白溶解变化以及雌激素对内皮细胞作用的研究。
Ann Hematol. 1993 Jul;67(1):33-6. doi: 10.1007/BF01709663.
8
Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.有出血倾向患者的凝血酶原激活肽F1+2水平。
Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S129-34.
9
Potential role of recombinant factor VIIa as a hemostatic agent.重组凝血因子VIIa作为止血剂的潜在作用。
Clin Adv Hematol Oncol. 2003 Feb;1(2):112-9.
10
High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA.凝血酶原的高F1.2片段、凝血酶 - 抗凝血酶III复合物（TAT）以及可溶性纤维蛋白血浆水平表明，在使用rt - PA进行局部区域溶栓治疗期间会诱发高凝状态。
Thromb Res. 1994 Jan 15;73(2):109-15. doi: 10.1016/0049-3848(94)90085-x.

本文引用的文献

1
Cardiopulmonary bypass parameters and hemostatic response to cardiopulmonary bypass in infants versus children.婴儿与儿童的体外循环参数及体外循环的止血反应
J Cardiothorac Vasc Anesth. 2008 Feb;22(1):53-9. doi: 10.1053/j.jvca.2007.06.006. Epub 2007 Aug 22.
2
Coagulopathy and inflammation in neonatal heart surgery: mechanisms and strategies.新生儿心脏手术中的凝血功能障碍与炎症：机制与策略
Ann Thorac Surg. 2006 Jun;81(6):S2360-6. doi: 10.1016/j.athoracsur.2006.02.072.
3
Emerging off-label uses for recombinant activated factor VII: grading the evidence.重组活化凝血因子 VII 的新兴非标签用途：证据分级
Crit Care Clin. 2005 Jul;21(3):611-32. doi: 10.1016/j.ccc.2005.04.001.
4
NovoSeven as a universal haemostatic agent.诺其作为一种通用止血剂。
Blood Coagul Fibrinolysis. 2000 Apr;11 Suppl 1:S107-11. doi: 10.1097/00001721-200004001-00020.

体外循环后新生儿止血标志物水平对活化凝血因子VII的反应

The Response of Hemostatic Marker Levels to Activated Factor VII in a Neonate following Cardiopulmonary Bypass.

作者信息

Eisses Michael J, Richards Michael, Joffe Denise, Geiduschek Jeremy M, Chandler Wayne L

机构信息

Department of Anesthesiology and Pain Medicine, Seattle Children's Hospital, University of Washington School of Medicine, 4800 Sand Point Way NE, Seattle, WA 98105, USA.

出版信息

Case Rep Med. 2009;2009:420152. doi: 10.1155/2009/420152. Epub 2009 Aug 31.

DOI:10.1155/2009/420152
PMID:19730751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2735071/
Abstract

The primary function of recombinant activated factor VII (rFVIIa) is to increase thrombin formation which leads to increased fibrin and less "bleeding." As a result, most of literature utilizes "bleeding" as the outcome measure with respect to rFVIIa. However, we report the actual effect of rFVIIa on changes in hemostatic markers such as prothrombin activation peptide F1.2, thrombin antithrombin complex (TAT), D-dimer, tissue plasminogen activator (tPA), and plasminogen activator inhibitor (PAI) in a neonate after cardiopulmonary bypass. A single dose of rFVIIa caused a 5.5-fold increase in F1.2, 3.5-fold increase in TAT, and a small increase in d-dimer compared to only a 1.5-fold increase, no increase, and a decrease, respectively, in two neonates undergoing the same procedure having not received rFVIIa. The patterns of change for tPA and PAI were similar.

摘要

重组活化因子VII（rFVIIa）的主要功能是增加凝血酶的形成，从而导致纤维蛋白增加和“出血”减少。因此，大多数文献将“出血”作为rFVIIa的疗效指标。然而，我们报告了rFVIIa对体外循环后新生儿凝血标志物变化的实际影响，这些标志物包括凝血酶原激活肽F1.2、凝血酶抗凝血酶复合物（TAT）、D - 二聚体、组织型纤溶酶原激活剂（tPA）和纤溶酶原激活剂抑制剂（PAI）。与两名接受相同手术但未接受rFVIIa的新生儿相比，单剂量rFVIIa使F1.2增加了5.5倍，TAT增加了3.5倍，D - 二聚体略有增加，而这两名未接受rFVIIa的新生儿F1.2仅增加了1.5倍，TAT未增加，D - 二聚体反而降低。tPA和PAI的变化模式相似。